Baldwin Brothers LLC Avadel Pharmaceuticals PLC Transaction History

Baldwin Brothers LLC

  • $1.43 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Jan 27, 2023
BUY
$5.02 - $10.0 $501 - $1,000
100 Added 25.0%
500 $0
Q4 2020

Jan 12, 2021
SELL
$5.03 - $7.95 $2,012 - $3,180
-400 Reduced 50.0%
400 $3,000
Q4 2018

Feb 01, 2019
SELL
$1.74 - $4.66 $14,790 - $39,610
-8,500 Reduced 91.4%
800 $2,000
Q3 2017

Oct 26, 2017
BUY
$8.35 - $10.5 $77,655 - $97,650
9,300
9,300 $98,000

Others Institutions Holding AVDL

# of Institutions
8
Shares Held
1.07M
Call Options Held
0
Put Options Held
0
View Full List

About AVADEL PHARMACEUTICALS PLC

AVDL Quotes by TradingView
  • Ticker AVDL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 60,581,300
  • Market Cap $650M
  • Description
  • Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...
More about AVDL
Track This Portfolio

Track Baldwin Brothers LLC Portfolio

Follow Baldwin Brothers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baldwin Brothers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Baldwin Brothers LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email